2U3 Stock Chart & Stats
€59.96
€0.94(1.59%)
At close: 4:00 PM EDT
€59.96
€0.94(1.59%)
Day’s Range― - ―
52-Week Range€52.42 - €77.08
Previous CloseN/A
Volume741.00
Average Volume (3M)1.34K
Market Cap
€29.70B
Enterprise Value€31.95K
Total Cash (Recent Filing)€1.66B
Total Debt (Recent Filing)€5.25B
Price to Earnings (P/E)41.5
Beta0.71
Next Earnings
Aug 10, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.65
Shares Outstanding499,700,000
10 Day Avg. Volume816
30 Day Avg. Volume1,343
Financial Highlights & Ratios
PEG Ratio39.53
Price to Book (P/B)1.79
Price to Sales (P/S)3.61
P/FCF Ratio21.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€76.81Price Target Upside28.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)2.96
Revenue Forecast (FY)€9.47B
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthLow leverage and a sizable equity base provide durable financial flexibility, enabling sustained R&D, capital placements and targeted buybacks without overextending. A strong balance sheet reduces refinancing risk and supports multi-year investment in product launches and global commercialization.
Product Innovation & Share GainsClear traction from newer IOLs and platform upgrades demonstrates durable competitive advantage: superior products drive market share gains in implantables, lift ASPs over time, and strengthen surgeon preference, which supports long-term consumables attach rates and pricing power across surgical franchises.
Installed Base Growth + Capital ReturnsRapid Unity equipment adoption expands the installed base that generates recurring consumable revenue and service income. Coupled with a sizeable repurchase program and dividend, management demonstrates confidence in cash generation and prioritizes capital allocation that can sustainably enhance shareholder value.
Bears Say
TTM Profitability & FCF SoftnessA notable step-down in trailing profitability and weaker FCF conversion undermines the stability of internally funded growth and buybacks. If cash conversion remains below earnings, it constrains investment capacity, raises sensitivity to shocks, and questions near-term sustainability of shareholder returns.
Tariff-driven Margin PressureHigher and uncertain import tariffs are a structural cost headwind that compresses gross margins and can persist until trade policy changes. Ongoing tariff exposure raises operating cost base and reduces margin optionality, especially for a global supply chain reliant on cross-border components.
China Weakness & Implantables CompetitionSlower growth in China and rising international competition in IOLs represent lasting market-share and growth risks. Weakness in key geographies and intense price/feature competition can limit near-term implantable expansion and weigh on higher‑margin segments tied to cataract procedure volumes.
Alcon News
2U3 FAQ
What was Alcon’s price range in the past 12 months?
Alcon lowest stock price was €52.42 and its highest was €77.08 in the past 12 months.
What is Alcon’s market cap?
Alcon’s market cap is €29.70B.
When is Alcon’s upcoming earnings report date?
Alcon’s upcoming earnings report date is Aug 10, 2026 which is in 8 days.
How were Alcon’s earnings last quarter?
Alcon released its earnings results on May 05, 2026. The company reported €0.71 earnings per share for the quarter, beating the consensus estimate of €0.683 by €0.028.
Is Alcon overvalued?
According to Wall Street analysts Alcon’s price is currently Undervalued.
Does Alcon pay dividends?
Alcon does not currently pay dividends.
What is Alcon’s EPS estimate?
Alcon’s EPS estimate is 0.65.
How many shares outstanding does Alcon have?
Alcon has 499,700,000 shares outstanding.
What happened to Alcon’s price movement after its last earnings report?
Alcon reported an EPS of €0.71 in its last earnings report, beating expectations of €0.683. Following the earnings report the stock price went down -10.616%.
Which hedge fund is a major shareholder of Alcon?
Currently, no hedge funds are holding shares in DE:2U3
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcon Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€76.81 (28.11% Upside)
€76.81 (28.11% Upside)
Blogger Sentiment
Bullish
DE:2U3 Sentiment 70%
Sector Average ―
Sector Average ―
Technicals
SMA
Negative
20 days / 200 days
Momentum
-25.74%
12-Months-Change
Fundamentals
Return on Equity
0.52%
Trailing 12-Months
Asset Growth
1.97%
Trailing 12-Months
Company Description
Alcon
Alcon Inc. is a global eye care enterprise dedicated to the research, development, manufacturing, and distribution of a comprehensive range of vision products for both eye care professionals and their patients worldwide. The company operates through two primary divisions. Its Surgical segment equips ophthalmic surgeons with advanced solutions for various procedures. This includes specialized equipment, diagnostic instrumentation, and implantable devices such as intraocular lenses (IOLs), alongside a full suite of consumables like viscoelastic substances, surgical solutions, and customized procedure kits. For cataract interventions, key offerings feature the Centurion Vision System, LenSx femtosecond laser, LuxOR surgical ophthalmic microscope, NGENUITY 3D visualization system, and ORA System for intra-operative measurements. Vitreoretinal surgeons benefit from systems like Constellation Vision, procedure packs, lasers, and a variety of specialized micro-instruments, including grieshaber and MIVS tools, scissors, forceps, medical-grade vitreous tamponades, and Hypervit vitrectomy probes. Refractive surgery innovations include WaveLight lasers and Contoura Vision for LASIK treatments, and the segment also provides the EX-PRESS glaucoma filtration device. Its IOL portfolio, prominently featuring AcrySof IQ, includes advanced technology lenses like PanOptix and ReSTOR, designed to correct presbyopia and astigmatism during cataract removal. The Vision Care segment addresses everyday eye health needs. It offers a diverse selection of contact lenses, including daily disposables, reusable options, and color-enhancing varieties. This segment also provides ocular health products for conditions such as dry eye, glaucoma, and allergies, in addition to contact lens care solutions, ocular vitamins, and redness-relieving drops. Prominent brands within this segment include TOTAL, PRECISION, DAILIES AquaComfort PLUS, Air Optix, Opti-Free, Clear Care, Tears Naturale, Genteal, ICAPS, and Vitalux. Founded in 1945, the company was initially known as Alcon Universal S.A. before rebranding as Alcon Inc. in December 2001. Its headquarters are located in Geneva, Switzerland.
2U3 Company Deck
2U3 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a largely constructive picture: solid top-line growth across surgical, vision care and ocular health, strong early adoption and share gains from new product launches (Unity, PanOptix Pro, Tryptyr, Total30), a meaningful equipment acceleration and a shareholder-friendly $1.5B repurchase plan. Offsetting this optimism were market headwinds (soft cataract volumes, China weakness), tariff-driven margin pressure, modest operational disruptions (Hydrus supply, Middle East shipping) and near-term margin timing (Q2 SG&A peak). Management maintained full-year guidance (5%–7% sales growth; 70–170 bps core operating margin expansion) and positioned the back half of 2026 for stronger contribution from new products, implying overall confidence in durable growth despite short-term noise.View all DE:2U3 earnings summaries2U3 Stock 12 Month Forecast
Average Price Target
€76.81
▲(28.11% Upside)